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Abstract
AIM: To determine the effect of procedural and cli-
nical factors upon C reactive protein (CRP) dynamics 
following transcatheter aortic valve implantation (TAVI).
METHODS: Two hundred and eight consecutive patients 
that underwent transfemoral TAVI at two hospitals 
(Imperial, College Healthcare NHS Trust, Hammersmith 
Hospital, London, United Kingdom and San Raffaele 
Scientific Institute, Milan, Italy) were included. Daily 
venous plasma CRP levels were measured for up to 
7 d following the procedure (or up to discharge). Pro-
cedural factors and 30-d safety outcomes according to 
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the Valve Academic Research Consortium 2 definition 
were collected. 
RESULTS: Following TAVI, CRP significantly increased 
reaching a peak on day 3 of 87.6 ± 5.5 mg/dL, P  
< 0.001. Patients who developed clinical signs and 
symptoms of sepsis had significantly increased levels of 
CRP (P  < 0.001). The presence of diabetes mellitus was 
associated with a significantly higher peak CRP level at 
day 3 (78.4 ± 3.2 vs  92.2 ± 4.4, P  < 0.001). There was 
no difference in peak CRP release following balloon-
expandable or self-expandable TAVI implantation (94.8 
± 9.1 vs  81.9 ± 6.9, P  = 0.34) or if post-dilatation 
was required (86.9 ± 6.3 vs  96.6 ± 5.3, P  = 0.42), 
however, when pre-TAVI balloon aortic valvuloplasty 
was performed this resulted in a significant increase in 
the peak CRP (110.1 ± 8.9 vs  51.6 ± 3.7, P  < 0.001). 
The development of a major vascular complication did 
result in a significantly increased maximal CRP release 
(153.7 ± 11.9 vs  83.3 ± 7.4, P  = 0.02) and there was 
a trend toward a higher peak CRP following major/life-
threatening bleeding (113.2 ± 9.3 vs  82.7 ± 7.5, P  = 
0.12) although this did not reach statistical significance. 
CRP was not found to be a predictor of 30-d mortality 
on univariate analysis. 
CONCLUSION: Careful attention should be paid to 
baseline clinical characteristics and procedural factors 
when interpreting CRP following TAVI to determine their 
future management.
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Core tip: Transcatheter aortic valve implantation (TAVI) 
results in increases in serum C reactive protein (CRP) 
levels reaching a peak at day 3 in all patients. CRP 
increase is further increased in patients with diabetes 
mellitus, those that underwent pre-TAVI balloon aortic 
valvuloplasty and patients that suffered major vascular 
complications. In addition to the bedside evaluation of 
patients, careful attention should be paid to baseline 
clinical characteristics and procedural factors when 
interpreting CRP to aid in the management and risk 
assessment of patients following TAVI.
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INTRODUCTION
Aortic stenosis (AS) is the most common valvular path­
ology in the elderly population with a prevalence of 
approximately 4.6% in patients greater than 75 years of 
age[1]. Whilst asymptomatic AS is associated with a low 
mortality[2], in those who develop symptoms, prognosis is 
very poor with a mortality of 50% within 2 years without 
treatment[3]. Whilst surgical aortic valve replacement 
(SAVR) remains the “gold standard” treatment, many 
of these elderly patients present with many co­existent 
comorbidities that render them inoperable or high­risk 
for SAVR. The emergence of transcatheter aortic valve 
implantation (TAVI) has revolutionised the treatment of 
these patients[4­8]. The transfemoral (TF) route is now the 
preferable TAVI vascular route due to shorter procedure 
and recovery times, and better clinical outcomes[9]. 
In spite of TAVI being less invasive, these frail, elderly 
patients are at increased risk of developing complications 
resulting in adverse outcomes. Post­procedural infection 
is a potentially life­threatening complication and has 
been reported to occur in approximately 20% of all 
patients[10,11]. In combination with the clinical evaluation 
of patients, the C reactive protein (CRP), an acute 
phase protein synthesized and released by the liver is 
commonly measured to aid in diagnosis. However, the 
CRP is non­specific for infection and misinterpretation 
can result in misdiagnosis, inappropriate antibiotic 
therapy (and associated adverse effects) and prolonged 
in­hospital stay. 
CRP is also a measure of inflammation that is thought 
to play a critical role in both the underlying pathogenesis 
of AS[12,13] with persistently high levels of circulating 
plasma inflammatory proteins following aortic valve 
intervention associated with increased cardiovascular and 
all­cause mortality[14,15]. SAVR results in greater activation 
of inflammatory pathways in comparison to TAVI with 
the TF access route being associated with the most att­
enuated inflammatory response[16]. Understanding CRP 
dynamics following TF TAVI is therefore critical in both 
the post­procedural management of these patients and 
predicting outcome.
The aim of this study was therefore to characterise 
CRP dynamics following TF TAVI and to identify clinical 
or procedural factors that may impact upon them. 
MATERIALS AND METHODS
Study population
Consecutive patients that underwent TF TAVI at two 
hospitals (Hammersmith Hospital, Imperial College 
Healthcare NHS Trust, London, United Kingdom and San 
Raffaele Scientific Institute, Milan, Italy) were included. 
All patients were treated for native severe AS with 
patients treated with TAVI devices for aortic regurgitation 
and for bioprosthesis degeneration excluded. A dedicated 
multidisciplinary “Heart Team” consisting of interven­
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tional cardiologist, cardiac surgeons, imaging specialists, 
general physicians and cardiac anaesthetists, discussed 
the management of all patients. All patients included in 
the study were of high surgical risk or inoperable on the 
basis of surgical risk scores (e.g., Euroscore) and clinical 
judgement to allow for other patient factors including 
frailty. 
Daily venous plasma CRP levels were measured for 
up to 7 d following the procedure (or up to discharge) 
using. 
Informed consent was provided by all patients for the 
procedure, subsequent clinical follow­up and analysis of 
data collected. 
TAVI procedure
Pre­operatively, all patients were evaluated with multi­
slice computed tomography or invasive angiography to 
determine the presence or absence of coronary artery 
disease and for the characterisation of the peripheral 
vasculature. The choice of prosthesis (balloon expandable 
Edwards Sapien XT or Sapien 3 (Edwards LifeSciences, 
Irvine, CA, United States) or self-expandable Medtronic 
CoreValve or Evolut R (Medtronic, Minnesota, MN, United 
States) and size was at the operator’s discretion. Patients 
treated with other devices were excluded due to their 
unavailability at both sites. At the time of TAVI, no 
patients had any clinical signs, symptoms of biochemical 
evidence of infection. All procedures were carried out 
under general anaesthesia or conscious sedation pro­
vided by a cardiac anaesthetist and were performed 
when possible by a fully percutaneous approach utilizing 
the cross­over technique and suture­mediated closure 
devices (Proglide and Prostar, Abbott Laboratories, IL, 
United States). Antibiotics were not administered to any 
patient routinely during the peri­operative period. 
Patient follow-up
Procedural outcomes in­hospital clinical outcomes were 
prospectively collected in a dedicated TAVI database. 
Longer­term follow­up was conducted by clinic visits. 
All definition of the clinical endpoints used were in con-
cordance with the Valve Academic Research Consortium 
2 (VARC-2) definitions[17]. Patients were deemed to have 
infection on the basis of clinical symptoms (e.g., dysuria), 
signs of infection (e.g., fever) and objective evidence 
(e.g., elevated white cell count, positive blood culture). 
The administration and choice of antibiotics was at the 
discretion of the treating physician.
Statistical analysis 
Continuous variables are presented as the mean ± 
standard error of the mean. Normality of each continuous 
variable was tested with the Kolmogorov­Smirnov test 
and differences were compared using the paired t­test. 
Categorical variables are presented as numerical values 
and percentages and were compared using the Fisher’s 
exact test. Cox proportional hazards regression analysis 
was performed to determine predictors of mortality. 
Receiver­operator characteristic (ROC) analysis was 
performed to identify the threshold for CRP as a binary 
classifier. All reported P­values were 2­sided, and values 
of P < 0.05 were regarded as statistically significant. 
Analyses were performed with SPSS version 21.0 (SPSS 
Inc., Chicago IL, United States) and GraphPad Prism 
version 5.0 (GraphPad, San Diego, CA, United States).
RESULTS
Patient population
Two hundred and eight patients underwent TF TAVI 
at both institutions during the study period and were 
included in the final analysis. The baseline characteristics 
of all patients are summarised in Table 1. As expected, 
the patient group were elderly (age: 81.4 ± 8.5 years) 
and of high surgical risk standard Euroscore 14.8% ± 
10.4%. 
Procedural characteristics and outcomes
All patients underwent TF TAVI with an overall procedu­
ral success rate of 98.1%. Procedural characteristics are 
summarised: Forty­nine percent of patients received 
a balloon expandable device [Edwards Sapien XT 
(27.4%) and Edwards Sapien 3 (21.6%)] and 51% of 
patient received a self-expandable prosthesis [Medtronic 
Corevalve (37.5%) and Medtronic Evolut R (13.9%)]. 
Seventy­three (35.1%) patients underwent pre­TAVI 
balloon aortic valvuloplasty (BAV). Thirty­seven patients 
(17.8%) required post­dilatation following TAVI for AR 
with 27 patients (13%) with residual grade ≥ 2 AR at 
the end of the procedure. Four patients (1.9%) required 
emergency cardiac surgery, one patient for coronary 
artery obstruction, two patients for left ventricular per­
foration and one patient for right ventricular perforation 
following temporary wire placement. There were 10 
(4.8%) peri­procedural deaths. Thirty­day outcomes 
according to the VARC­2 criteria are summarised in Table 2. 
CRP dynamics
The baseline CRP (measured in 87.7% of patients) was 
Variable All patients (n  = 208)
Age (yr) 81.4 ± 0.9
Female (%)   57 (27.4)
Diabetes mellitus (%)   34 (16.3)
Hypertension (%) 122 (58.7)
Dyslipidemia (%)   65 (31.3)
History of smoking (%)   34 (16.3)
NYHA Ⅲ or Ⅳ (%)   94 (45.2)
Previous MI (%)   24 (11.5)
Previous CABG (%)   37 (17.8)
Previous PCI (%)   40 (19.2)
Cerebrovascular disease (%) 19 (9.1)
eGFR < 60 mL/min per 1.73 m2 (%)   42 (20.2)
Logistic EuroScore (%) 14.8 ± 1.4
Table 1  Baseline patient characteristics
NYHA: New York Heart Association; MI: myocardial infarction; CABG: 
Coronary artery bypass grafting; PCI: Percutaneous coronary intervention; 
eGFR: Estimated glomerular filtration rate.
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8.9 ± 2.5 mg/dL for total study population. Following 
TAVI this significantly increased reaching a peak on day 
3 of 87.6 ± 5.5 mg/dL (measured in 77.6% of patients), 
P < 0.001 (Figure 1A). As would be expected, patients 
who developed clinical signs and symptoms of sepsis 
had significantly increased levels of CRP (n = 8) when 
compared to all patients which at day 3 was 187.7 ± 
6.1 representing a 21­fold increase when compared to 
baseline levels (P < 0.001, Figure 1B).
Clinical impact upon CRP dynamics
Following exclusion of patients with clinical evidence of 
infection, peak (day 3) CRP levels were compared to 
determine the impact of baseline clinical factors upon 
maximal CRP release following TAVI. The presence of 
diabetes mellitus was associated with a significantly 
higher peak CRP level at day 3 (78.4 ± 3.2 vs 92.2 ± 
4.4, P < 0.001). The presence of hypertension (75.2 ± 
4.1 vs 93.1 ± 3.2, P = 0.22), previous PCI (70.6 ± 3.9 
vs 82.2 ± 5.2, P = 0.39), previous cardiac surgery (87.4 
± 3.1 vs 93.9 ± 3.4, P = 0.65) or smoking (99.6 ± 3.7 
vs 78.1 ± 3.3, P = 0.31) did not impact upon the peak 
CRP following TAVI. 
Procedural impact upon CRP dynamics
There was no difference in peak CRP release following 
balloon­expandable or self­expandable TAVI implantation 
(94.8 ± 9.1 vs 81.9 ± 6.9, P = 0.34) or if post­dilatation 
was required (86.9 ± 6.3 vs 96.6 ± 5.3, P = 0.42). 
There was a difference in maximal CRP release when 
pre­TAVI balloon aortic valvuloplasty was performed 
(110.1 ± 8.9 vs 51.6 ± 3.7, P < 0.001). Peak CRP was 
not found to be different between patients with residual 
≥ 2 AR and those that had residual < 2 AR (71.9 ± 
7.4 vs 88.9 ± 7.9, P = 0.28). The development of a 
major vascular complication did result in a significantly 
increased maximal CRP release (153.7 ± 11.9 vs 83.3 
± 7.4, P = 0.02) and there was a trend toward a higher 
peak CRP following major/life­threatening bleeding (113.2 
± 9.3 vs 82.7 ± 7.5, P = 0.12) although this did not 
reach statistical significance. 
CRP as a predictive tool
Both CRP levels at baseline [hazard ratio (HR) per unit 
increase 0.98, 0.94­1.03, P = 0.42] and peak levels at 
day 3 (HR per unit increase: 1.01, 0.98­1.02, P = 0.18) 
were not found to be predictors of 30­d mortality on 
univariate analysis. We also did not find the magnitude of 
change in CRP (the difference between peak and baseline 
levels) to be a predictor of 30­d mortality (HR per unit 
increase: 0.92, 0.83­1.14, P = 0.33). ROC analysis 
further confirmed that both baseline [area under the 
curve (AUC): 0.42] and peak levels (AUC: 0.48) of CRP 
was a poor predictive tool for 30­d mortality in this study 
population.
DISCUSSION
The principal findings are: (1) CRP universally increases 
following TAVI reaching a peak at day 3; (2) the presence 
of diabetes mellitus was associated with a significant 
increase in the peak CRP following TAVI; (3) procedurally, 
the use of balloon aortic valvuloplasty during the pro­
cedure and the development of a major vascular com­
plication resulted in a significant increase in the peak 
CRP; and (4) the peak CRP did not predict 30­d adverse 
outcomes.
Inflammation plays a central role in the pathoge­
nesis and progression of AS[13,18,19]. The treatment of 
AS also results in activation of inflammatory pathways 
with more invasive treatment options (e.g., SAVR) 
associated with more inflammation in comparison to 
less invasive treatment options (e.g., TF TAVI)[16]. In 
addition to the magnitude of inflammation, persistently 
elevated markers of inflammation have been shown 
to be negatively associated with outcomes including 
mortality[14,20,21]. In agreement with previous reports, 
we found that CRP increased in all patients following TF 
TAVI reaching a peak level at day 3[16,22]. 
CRP in diabetes mellitus has been shown to be a 
predictor of cardiovascular events and outcomes[23,24]. 
After excluding patients with clinical signs and symptoms 
of infection we found that the presence of diabetes 
mellitus resulted in a significantly increased peak release 
in CRP following TAVI. This may explain worse outcomes 
in this patient sub­group[25] and should be considered 
when interpreting CRP results following TAVI and also 
when counselling patients with regards to risk pre­
procedurally. We did not find any other baseline clinical 
characteristic (e.g., smoking, hypertension) to have an 
impact upon CRP dynamics following TAVI. 
The impact of specific procedural factors upon CRP 
dynamics is poorly characterised in patients undergoing 
TF TAVI. We did not find a difference in the peak CRP 
between patients that were treated with a BE or SE valve 
possibly suggesting that they are both equally traumatic. 
Interestingly, the use of pre­implantation BAV was 
associated with a significant increase in the peak CRP at 
All patients (n  = 208)
All-cause death  12 (5.8)
Coronary obstruction (%)      1 (0.05)
Stroke    9 (4.3)
PPM implantation    38 (18.3)
Minor vascular complication    8 (3.8) 
Major vascular complication    8 (3.8)
Minor bleed    34 (16.3)
Major bleed    23 (11.1)
Life-threatening bleeding    8 (3.8)
Valve related dysfunction 0 (0)
Table 2  Thirty-day outcomes
PPM: Permanent pacemaker implantation. 
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day 3, whilst the requirement for post­dilatation or the 
extent of residual AR did not impact upon maximal CRP 
release. This finding may represent the increased trauma 
to the native valvular apparatus and systemic debris 
shower resulting in greater release of CRP, although this 
may also reflect disease severity of the native valve that 
required a BAV rather than direct valvular implantation. 
Nonetheless, it is important for physicians managing 
patients following TAVI to be aware of the procedural 
specifics when interpreting CRP results in the post­
operative period. 
Unsurprisingly, the development of a major vascular 
complication resulted in a greater release of CRP, likely 
reflecting further trauma associated with peripheral 
vessel intervention and also longer procedural times. 
The requirement for a blood transfusion, in our study 
population, did not impact upon CRP dynamics in the 
post­procedural period. 
CRP has been shown to be a useful prognostic tool[22] 
following TAVI, however in our study population, this 
was not found to be the case, possibly due to the relative 
small numbers of patients and short follow­up.
Study limitations
This study has some limitations. This was a retrospec­
tive study with treatment strategy (e.g., prosthesis 
selection, use of BAV) at the operator’s discretion and so 
the effect of selection bias cannot be excluded. Patient 
numbers were relatively small with limited follow­up 
and so the study may be underpowered to detect the 
predictive value of CRP upon outcomes. Finally, we did 
not measure the role of other markers of inflammation 
that in combination with CRP may have augmented its 
usefulness, although this study reflects routine clinical 
practice and makes the results directly applicable to a 
contemporary TAVI service.
In conclusion, TAVI results in increases in serum 
CRP levels reaching a peak at day 3 in all patients. CRP 
increase is further increased in patients with diabetes 
mellitus, those that underwent pre­TAVI BAV and patients 
that suffered major vascular complications. In addition 
to the bedside evaluation of patients, careful attention 
should be paid to baseline clinical characteristics and 
procedural factors when interpreting CRP to aid in the 
management and risk assessment of patients following 
TAVI.
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